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1684-1182/Copyright ª 2014, Taiwan S
BY-NC-ND license (http://creativecomBackground: To establish the seroepidemiologic data of hepatitis A virus (HAV) vaccine-
preventable HAV diseases among school children (7e12 years old) attending elementary
schools in New Taipei City, Taiwan. This is a pilot study of an ongoing nationwide study, and
will be the reference for a national immunization program.
Methods: The school children were selected for samplings, based on a multistage stratified
sampling method that included 14 variables (4 socioeducational variables, 4 socioeducational
variables, and 6 medical facilities’ variables). The 29 administrative districts of New Taipei
City were categorized into five strata. In total, 936 school children from 14 schools were re-
cruited and bled for the serologic tests of HAV by enzyme-linked immunosorbent assay
method.
Results: The seropositive rate for HAV was 8.33% among the 936 children. From each school,
the difference in the seropositive rate for HAV ranged 0e18.75%. There was no significant dif-
ference between each stratum (pZ 0.059) or grade (pZ 0.570); however, there was a differ-
ence between schools in the first stratum (p Z 0.033) that was associated with different
vaccination rates. This study also revealed a significantly greater seropositive rate in the vacci-
nation group (p < 0.001) and in females (p Z 0.02).
Conclusion: The seropositive rate for the HAV was <10% and was mostly associated with the
vaccination status. Because of the low HAV vaccination rate and low seropositive rate for
the HAV, an effective hepatitis A vaccine is a useful tool to prevent HAV infection. It is worthyt of Pediatrics, Chang Gung Children’s Hospital, Number 5, Fu-Hsin Street, Kweishan 333, Taoyuan,
ail.com (Y.-C. Hsieh), ychuang@cgmh.org.tw (Y.-C. Huang).
.08.022
ociety of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
744 S.-L. Tseng et al.to discuss whether to include the HAV vaccine as part of a routine vaccination program in
Taiwan.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Acute hepatitis A virus (HAV) infection is the most common
form of acute viral hepatitis throughout the world. It is
more common in regions of the world with poor sanitation
and insufficient safe water. In the developing world,
approximately 90% of children have been infected by the
age of 10 years and thus are immune by adulthood.1 Acute
hepatitis A virus often occurs in outbreaks in moderately
developed countries.2,3 In young children, acute HAV
infection is often asymptomatic. In older children and
adults, the infection is usually symptomatic with jaundice
occurring in >70% of patients.4 Fulminant hepatitis occurs
in approximately 8% of patients.5
Hepatitis A vaccine effectively prevents HAV infec-
tion.6,7 In general, approximately 95e100% of children
older than 2 years who receive one dose of HAV vaccine will
produce protective antibodies.8 The hepatitis A vaccine
used in Taiwan is an inactivated virus vaccine. The hepatitis
A vaccine is freely provided by the government for children
living in aboriginal townships and neighboring townships (in
total, 30 townships) The HAV vaccine is self-paid and mostly
administered in private sectors. The recommended vacci-
nation schedule is one dose at the age of at least 1 year and
a second dose 6e12 months later (in total, 2 doses).
In the early 1970s, > 90% of Taiwanese adults had anti-
HAV antibodies, and most of them had contracted HAV
infection during childhood.8,9 During 1975e1976, the sero-
positive rate of anti-HAV immunoglobulin G (IgG) was 15.2%
for children under 6 years of age, 15e25% for children 6e10
years of age, and up to 50e86% for adolescents 11e15 years
of age.10 With economic growth, people in Taiwan have
made progress in sanitation and thus reduce the pollution
of drinking water and food. The improvements in social and
personal sanitation reduce the transmission of infectious
agents via the fecaleoral route and reduces the opportu-
nities for HAV infection. In 1984, one study conducted in
Taipei showed that the seroprevalence of hepatitis A
infection was only approximately 1% for children under
6 years of age, approximately 5% for children aged 6e10
years, and 10e13% for children aged 10e15 years.11 Few
people had experienced HAV infections in childhood, and
HAV infection caused more severe symptoms when the
infection occurred in adulthood. With the accumulation of
nonimmune people, a large-scale of HAV outbreak can
happen such as the 1988 epidemic of hepatitis A in Shanghai
that involved 30,000 cases.12
Hepatitis A vaccine has been used in Taiwan for years,
primarily in the private sectors, and may be included in an
expanded program of immunization. However, for at least
10 years, there have been no seroepidemiologic data for
the targeted population. Therefore, we conducted thisstudy, which was supported by the Centers for Diseases
Control of Taiwan (CDC Taiwan), to evaluate the seropre-
valence of HAV among Taiwanese school children aged 7e12
years.
Materials and methods
Ethics statement
In 2012, the Institutional Review Board of the Chang Gung
Memorial Hospital, Taoyuan, Taiwan reviewed and
approved the study proposal. Written informed consent was
obtained from all participants or their guardians.
Study populations and selection of patients
From September 2012 to June 2013, a cross-sectional survey
of HAV-specific IgG antibody in a population of elementary
school children (age, 7e12 years) was conducted in New Tai-
pei City. New Taipei City comprises 29 administrative districts
and is the second largest special municipality in northern
Taiwan. The elementary students residing in this city
accounted for 16.5% of thewhole population of primary school
children in Taiwan in 2012. A multistage stratified systematic
sampling design was employed to obtain samples.13 The 29
administrative districts of New Taipei City were arbitrarily
classified into five strata, based on 14 variables that included
four demographic variables [i.e., the population density
(persons/km2); the proportion of the population older than 65
years; the proportion of population younger than 15 years; the
proportion of the population younger than 6 years]; four
socioeducational variables (i.e., the number of low-income
households per 10,000 people; the number of near-poor
households per 10,000 people; the proportion of agricultural
population; and the proportion of population with college
degree or above); and six medical facility variables (i.e., the
number of physicians per 10,000 people; the number of
nursing staffs per 10,000 people; the number of nursing staffs
in health centers per 10,000 people; the number of medical
personnel in health centers per 10,000 people; the number of
staff in health centers per 10,000 people and the number of
health care settings per 10,000 people). Elementary schools in
each stratum were selected with selection probability pro-
portional to their size (PPS).13 One class was drawn from each
grade in a sampled school (i.e., in total, 6 classes were drawn
from each sampled school). In each selected school, the
number of students in each classwas also selectedwith PPS. In
each class, students were finally selected randomly. Students
(n Z 558) were accordingly selected from six schools in
Stratum 1; 130 students, from two schools in Stratum 2; 66
students, from two schools in Stratum 3; 140 students, from
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schools in Stratum 5. In total, at least 901 students were ob-
tained.We subsequently planned to recruit 936 students from
the selected schools, as shown in Fig. 1. All study participants
were manifestly healthy without acute illness at blood
drawing. Past medical history was obtained by questionnaire
from each participant and the information of vaccination
status was reliably obtained by vaccination records.
Each student included in this study had 5e10 mL of blood
drawn for HAV antibodies examination by the qualitative
Liaison Anti-HAV IgG chemiluminescence assay (Diasorin,
Saluggia, Italy). The antibody test procedure followed the
original company’s recommendation. The test was
repeated if the first operation had indeterminate results,
and was recorded as “negative” if the second results
remained indeterminate.
Statistical analysis
A comparison of the seropositive rate or vaccination rate
between different groups was tested by the Chi-square
test. A multivariate logistic regression model was used to
evaluate the factors of seropositive HAV. Data analyses
were performed using SPSS software version 17.0 (SPSS Inc.,
Chicago, IL, USA). A p value <0.05 was considered statis-
tically significant.
Results
This study recruited 936 school children from 14 schools.
Among the 936 students, anti-HAV IgG was positive forFigure 1. Study flow diagram o78 children, which gives a seropositive rate of 8.33%. For
each stratum, the difference in the seropositive rate
ranged from 0% (the lowest, Stratum 5) to 10.24% (the
highest, Stratum 1), but there was no statistical signifi-
cance between the strata (p Z 0.059). There was no sta-
tistical difference of vaccination rate between the strata
(p Z 0.1) (Table 1). For each participant school, the sero-
positive rate for anti-HAV IgG ranged 0e18.75%. The sero-
positive rate was statistically significantly different
between the schools in Stratum 1 (pZ 0.033), ranging from
6.25% for San-Zhong school and Zhong-Gang school to
18.75% for Ju-Guang school; however, there was no statis-
tically significant differences between the schools in the
second to fifth strata. There were also no statistically sig-
nificant differences in the seropositive rate between the
grades, and it ranged from 5.13% (the lowest, Grade 5) to
10.26 (the highest, Grade 2; p Z 0.57; Table 2).
The seroprevalence of anti-HAV IgG was significantly
higher in females than in males (p Z 0.02; Table 3). How-
ever, the vaccination rates between males and females,
based on questionnaire data and vaccination records of the
CDC Taiwan, were not significantly different [7.5% (male) vs.
9.5% (female); p Z 0.3; data not shown]. The HAV sero-
positive rate in the participants was significantly associated
with the vaccination rate (p < 0.001; Table 3). Thirty-nine
(95.12%) of 41 people who received two doses of the HAV
vaccine were seropositive for HAV. Sixteen (41.03%) of
39 people who received one dose of the HAV vaccine were
positive for anti-HAV IgG, whereas only 23 (2.69%) of 856
people who had never received the HAV vaccine had a
positive result. Multiple logistic regression analysis showed
that the independent factors for anti-HAV seropositivityf the sampling. N Z number.
Table 1 Results of seropositivity and vaccination against hepatitis A virus for school children in New Taipei City, stratified by
administrative area strata
School (administrative district) No. of students M:F ratio Seropositive, N (%) Vaccination, N (%)
1st stratum 576 0.97 59 (10.24) 61 (10.59)
Zhong-Shan (Ban-Qiao) 96 0.81 11 (11.46) 11 (11.46)
San-Zhong (San-Zhong) 96 0.92 6 (6.25) 10 (10.42)
Zhong-Gang (Xin-Zhuang) 96 0.85 6 (6.25) 7 (7.29)
Lu-Zhou (Lu-Zhou) 96 1.09 7 (7.29) 3 (3.13)
Ji-Mei (San-Zhong) 96 1.29 11 (11.46) 9 (9.36)
Ju-Guang (Ban-Qiao) 96 0.96 18 (18.75) 21 (21.86)
2nd stratum 120 0.82 8 (6.67) 6 (5.00)
Cheng-Fu (San-Xia) 60 0.62 2 (3.33) 2 (3.33)
Xin-Xing (Dan-Shui) 60 1.07 6 (10) 4 (6.67)
3rd stratum 72 0.64 2 (2.78) 3 (4.17)
Jin-Mei (Jin-Shan) 36 0.71 1 (2.78) 0 (0)
Jin-Long (Xi-Zhi) 36 0.57 1 (2.78) 3 (8.33)
4th stratum 144 0.95 9 (6.25) 10 (6.94)
Gan-Yuan (Shu-Lin) 72 1.00 4 (5.56) 4 (5.56)
Wu-Gu (Wu-Gu) 72 0.89 5 (6.94) 6 (8.33)
5th stratum 24 2.00 0 (0) 0 (0)
Shi-Ding (Shi-Ding) 12 5.00 0 (0) 0 (0)
Shuang-Xi (Shuang-Xi) 12 1.00 0 (0) 0 (0)
Total 936 0.93 78 (8.33) 80 (8.54)
746 S.-L. Tseng et al.were female sex [odds ratio (OR) Z 2.0; 95% confidence
interval (CI)Z 1.04e03.8; pZ 0.04] and vaccination against
HAV (OR Z 82.3; 95% CI Z 43.3e156.4; p < 0.001).
Discussion
This study showed that the HAV seropositive rate was 8.33%
in elementary school children in New Taipei City. TheTable 2 Distribution of the seropositive rate of hepatitis A
virus for elementary school children in New Taipei City,
stratified by class grades
Grade Number of
people
Positive
results (N )
Positive
rate (%)
p
1 156 13 8.33 0.570
2 156 16 10.26
3 156 15 9.62
4 156 15 9.62
5 156 8 5.13
6 156 11 7.05
Total 936 78 8.33
Table 3 Factors associated with positive anti-hepatitis A virus
Factor Patients with positive
anti-HAV antibody, n (%)
N Z 78
Patients without anti-H
antibody, n (%)
N Z 858
Female sex 50 (64.1) 434 (50.6)
Unvaccinated 23 (29.5) 833 (97.1)
1 dose 16 (20.5) 23 (2.7)
2 doses 39 (50) 2 (0.2)
CI Z confidence interval; HAV Z hepatitis A virus; OR Z odds ratio.seropositive rate for school children was not significantly
different with regard to administrative area, school, and
class grade. In the first stratum, the seropositive rate for
the children in Ju-Guang school was highest and so was its
vaccination rate (21.86%), whereas the children in San-
Zhong school and Zhong-Gang school with the lowest sero-
positive rate had the two lowest vaccination rates at 1.2%
and 0.5%, respectively. The seropositive rate was in parallel
with the HAV vaccination rate. Parental awareness and
physician’s suggestion are associated with a higher vacci-
nation rate. Ju-Guang school is situated in the Ban-Qiao
area, the urban area of New Taipei City, and thus parents of
these school children may have a higher awareness of the
vaccine and a greater willingness to vaccinate their
children.
We further analyzed vaccination and seropositivity. We
found that the presence of anti-HAV antibody was signifi-
cantly associated with the vaccination status, and the
seropositive rate was higher in children with a history of
two doses of the vaccination, compared to children with
one dose. This finding was compatible with previous studies
showing that individuals vaccinated with two or more doses
of hepatitis A vaccine had a seroprotective level ofantibody in 936 school children
AV Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
1.7 (1.1e2.8) 0.02 2.0 (1.04e3.8) 0.04
79.7 (42.5e149.4) <0.001 82.3 (43.3e156.4) <0.001
Hepatitis A virus seroepidemiology in Taiwan 747antibodies for at least 14 years after vaccination.14 Kinetic
models of antibody decay indicate that the duration of
protection is likely to be at least 20 years and possibly
lifelong.15,16 This study revealed that the seropositive rate
for children receiving one dose of HAV vaccine was only
41.03%, whereas the rate was increased to 95.12% for
children receiving two doses. A previous study shows that
the seropositive rate was increased to 100% for vaccinees
21e137 days after one dose of HAV vaccination15; however,
there were no studies to evaluate the duration that the
seroprotection level of antibodies remained after one dose
of HAV vaccine. This study indicated that the antibody
waned 5e12 years after one dose of HAV vaccine.
In the present study, there were 23 students who had a
positive result for anti-HAV antibody but no history of HAV
vaccination. We could only presume that these 23 students
may have obtained their anti-HAV antibody from a natural
infection. Because most children with HAV infection are
asymptomatic and a tour to China or Southeast countries is
common for the children in Taiwan, the issue of when and
where these children contracted the HAV infection could
not be identified and remained unknown from the
questionnaire.
The seropositive rate of anti-HAV IgG for elementary
school children (age, 7e12 years) in the present study was
higher than that in previous studies from Taiwan in which
the seropositive rate ranged from <0.5% to 1.4%.17e19 The
higher seroprevalence of anti-HAV IgG in this study may be
because of the higher vaccination rate of HAV in the pre-
sent study population. This study also identified female sex
as significantly associated with the seropositive rate among
school children in New Taipei City in Taiwan. The sex dif-
ference in human immunity has been recognized in many
vaccines against a variety of diseases, including the HAV
vaccine.20e23
Because of the large population of school-aged children
susceptible to HAV infection, we believe an issue is whether
HAV vaccine should be included in the routine vaccination
program in Taiwan to achieve a better herd immunity
against HAV. However, this study was only a pilot study
supported by the CDC-Taiwan to preliminarily understand
the seroepidemiology of this population group. A nation-
wide survey for the seroprevalence of children and ado-
lescents should be conducted to understand better the
seroepidemiology of this vulnerable population. In addi-
tion, the cost-effectiveness of HAV in mass vaccination also
should be evaluated before including HAV in a routine
vaccine program in Taiwan.Conflicts of interest
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